Higher doses tested for Tough-to-Treat schizophrenia

NCT ID NCT00539071

Summary

This study tested whether higher doses of a long-acting injectable antipsychotic medication (risperidone) work better than standard doses for people with schizophrenia or schizoaffective disorder whose symptoms aren't well controlled. 160 participants who hadn't responded well to their current medication received either the standard dose or a higher dose for six months. Researchers compared how much symptoms improved between the two groups.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Vanderbilt Psychiatric Hospital

    Nashville, Tennessee, 37212-8645, United States

Conditions

Explore the condition pages connected to this study.